Innate Immunity, Inflammation and Colorectal Cancer

2013 ◽  
pp. 4-10
Author(s):  
Kepeng Wang ◽  
Sergei Grivennikov ◽  
Michael Karin
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity

Abstract A110: Associations between genetic variations in inflammation and innate immunity pathways and colorectal cancer

2012 ◽  
Vol 5 (11 Supplement) ◽  
pp. A110-A110
Author(s):  
Hansong Wang ◽  
Darin Taverna ◽  
Daniel O. Stram ◽  
Iona Cheng ◽  
Lynne R. Wilkens ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity ◽  
Genetic Variations

scholarly journals Immunotherapy in Solid Tumors and Gut Microbiota: The Correlation—A Special Reference to Colorectal Cancer

Cancers ◽  
2020 ◽  
Vol 13 (1) ◽  
pp. 43
Author(s):  
Asimina Koulouridi ◽  
Ippokratis Messaritakis ◽  
Nikolaos Gouvas ◽  
John Tsiaoussis ◽  
John Souglakos
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity ◽  
Gut Microbiota ◽  
Solid Tumors ◽  
Immune Checkpoint Inhibitors ◽  
Checkpoint Inhibitors ◽  
Immune Surveillance ◽  
Microbiota Composition ◽  
Innate And Adaptive Immunity ◽  
Gut Microbiota Composition

Over the last few years, immunotherapy has been considered as a key player in the treatment of solid tumors. Immune checkpoint inhibitors (ICIs) have become the breakthrough treatment, with prolonged responses and improved survival results. ICIs use the immune system to defeat cancer by breaking the axes that allow tumors to escape immune surveillance. Innate and adaptive immunity are involved in mechanisms against tumor growth. The gut microbiome and its role in such mechanisms is a relatively new study field. The presence of a high microbial variation in the gut seems to be remarkably important for the efficacy of immunotherapy, interfering with innate immunity. Metabolic and immunity pathways are related with specific gut microbiota composition. Various studies have explored the composition of gut microbiota in correlation with the effectiveness of immunotherapy. Colorectal cancer (CRC) patients have gained little benefit from immunotherapy until now. Only mismatch repair-deficient/microsatellite-unstable tumors seem to respond positively to immunotherapy. However, gut microbiota could be the key to expanding the use of immunotherapy to a greater range of CRC patients.

scholarly journals Salmonella-mediated therapy targeting indoleamine 2, 3-dioxygenase 1 (IDO) activates innate immunity and mitigates colorectal cancer growth

2019 ◽  
Vol 27 (3-4) ◽  
pp. 235-245 ◽  
Author(s):  
Thuy Phan ◽  
Vu H. Nguyen ◽  
Marcela S. D’Alincourt ◽  
Edwin R. Manuel ◽  
Teodora Kaltcheva ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity ◽  
Cancer Growth ◽  
Indoleamine 2

Abstract 245: Genetic variation related to innate immunity and colorectal cancer risk

2018 ◽  
Author(s):  
Jessica Citronberg ◽  
Barbara Banbury ◽  
Andrew T. Chan ◽  
Peter T. Campbell ◽  
Graham Casey ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Innate Immunity ◽  
Genetic Variation ◽  
Cancer Risk ◽  
Colorectal Cancer Risk
Sign in / Sign up

Export Citation Format

Share Document